Aldeyra Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
ALDX$0.63-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2024 and 2023
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $54,527,092 | $142,823,016 |
| Marketable securities | 46,624,180 | — |
| Prepaid expenses and other current assets | 2,921,206 | 4,987,317 |
| Total current assets | 104,072,478 | 147,810,333 |
| Deferred offering costs | 267,261 | — |
| Fixed assets, net | — | 5,764 |
| Right-of-use assets | 266,955 | 510,814 |
| Total assets | $104,606,694 | $148,326,911 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $180,453 | $1,338,057 |
| Accrued expenses | 12,118,367 | 5,536,464 |
| Current portion of debt | 31,372 | 15,146,546 |
| Operating lease liabilities | 271,631 | 239,183 |
| Deferred collaboration revenue | 6,000,000 | — |
| Total current liabilities | 18,601,823 | 22,260,250 |
| Deferred collaboration revenue, long-term | — | 6,000,000 |
| Operating lease liabilities, long-term | — | 271,631 |
| Long-term debt, net of current portion | 15,000,000 | — |
| Total liabilities | 33,601,823 | 28,531,881 |
| Commitments and contingencies (Notes 3, 9, & 13) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding | — | — |
| Common stock, voting, $0.001 par value; 150,000,000 authorized and 59,648,278 and 59,195,951 shares issued and outstanding, respectively | 59,648 | 59,196 |
| Additional paid-in capital | 521,018,373 | 513,994,982 |
| Accumulated other comprehensive income | 37,442 | — |
| Accumulated deficit | (450,110,592) | (394,259,148) |
| Total stockholders’ equity | 71,004,871 | 119,795,030 |
| Total liabilities and stockholders’ equity | $104,606,694 | $148,326,911 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.